Industry P Pharmaceutical Executive
Building an Organization that can Absorb the Pace of Change
Pharma leaders on redesigning workflows for agility—and how AI is compressing timelines and reshaping roles across tech, marketing, and MLR.
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P Pharmaceutical Executive
Pharma leaders on redesigning workflows for agility—and how AI is compressing timelines and reshaping roles across tech, marketing, and MLR.
Industry P Pharmaceutical Executive
Pharma leaders on balancing discipline and flexibility—and staying consistent in strengths and values as business contexts constantly shift.
Industry P Pharmaceutical Executive
Pharma leaders on building trust in AI through transparency and validation—and helping teams adapt as analytics roles evolve with the technology.
Industry P Pharmaceutical Executive
Pharma leaders on navigating agentic AI without a playbook—and keeping patient and physician benefit as the north star through uncertainty.
Industry P Pharmaceutical Executive
Pharma leaders on building global strategy from a product’s universal truth—then adapting locally and adjusting plans as new data emerges.
Industry P Pharmaceutical Executive
Pharma leaders on sitting with uncertainty before acting—and tailoring communication to resonate with investors and scientific audiences alike.
Research
Inside Precision Medicine
A new study suggests that VEGF-C expression in cells surrounding breast tumors, rather than the cancer cells themselves, may help predict lymph node metastasis and support more personalized surgical treatment. The post New Breast Cancer Biomarker Could Help Guide Less Invasive Su…
Industry
Inside Precision Medicine
Preeclampsia-focused biotech Emvena Therapeutics has launched in Philadelphia and plans to use targeted mRNA therapeutics to treat the disorder. The post Emvena Therapeutics Emerges from Stealth to Target Preeclampsia appeared first on Inside Precision Medicine.
Manufacturing
Fierce Pharma
From Discovery to Commercial Supply: Managing Peptide Manufacturing Risks scox Fri, 11/06/2026 - 14:57 Tue, 12/15/2026 - 09:00 Resource Type Webinar Dr. Chen Liu Promotion End Mon, 05/17/2027 - 08:42 How can you deliver peptide material on time, maintain quality, and prepare for…
Industry P Pharmaceutical Executive
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.
Software L Latch Bio
We gave models 35 challenging rare disease cases where they have to request what data they needed
Software W Weekly Tech+Bio
We have started this tracker to regularly update the community about where the progress goes with virtual cells and companies focusing on this paradigm.
Industry
Drug Discovery and Development
Moderna is preparing to seek approval for intismeran autogene, the personalized cancer vaccine it is developing with Merck, according to its November 6 earnings release. The therapy could open a new source of revenue beyond the infectious disease vaccines that built its business.…
Industry
MedTech Dive
The CEO change was unexpected and prompted a stock selloff Friday, analysts said, but the new chief executive is prepared for the role.
Software
Fierce Pharma
Agentic AI Is Rewriting The Pharma Marketing Playbook scox Fri, 11/06/2026 - 12:43
Clinical P Pharmaceutical Commerce
Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.
Industry
GEN
"Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement. The post Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Th…
Industry
BioPharma Dive
The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.
Industry
European Biotechnology
The post Turn bioprocess data into timely, transferable process control appeared first on European Biotechnology Magazine.
Industry
GEN
The results of a study found that women with higher blood levels of two common PFAS were more likely to develop estrogen receptor-negative breast cancer, saying their results have important public health implications. The post ER-Negative Breast Cancer Risk Linked with Blood Leve…
Industry
Inside Precision Medicine
More than a decade after Theranos collapsed, diagnostics companies are pursuing its vision and questioning whether the lab needed to fit in a box. The post You Can See Something: How Diagnostics Companies Are Rising from the Ashes of Theranos appeared first on Inside Precision Me…
Manufacturing B BioProcess International
The investment is in response to an increased demand in GLP-1s and other peptide products.
Industry
STAT Biotech
New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
Agriculture
AgriBusiness Global
In this episode of the AgriBusiness Global Report, Nicolas Potrie, Director of Tafirel, discusses the Mercosur-EU agreement and its impact on agricultural input markets. The post AgriBusiness Global Report: How the Mercosur-EU Agreement Reshapes the Agribusiness Market appeared f…
Industry
Clinical Trials Arena
This study points to a possible shift in how lung cancer is tackled, from finding tumours early to recognising the conditions that allow them to develop. The post Predicting lung cancer risk goes beyond age and smoking history appeared first on Clinical Trials Arena.
Clinical B BioPharm International
Russell Miller, SVP of Global Sales and Marketing at Enzene, explains why he believes biologics manufacturing is at an inflection point as the industry moves beyond decades of fed-batch processing.
Manufacturing
Pharmaceutical Technology
Lonza’s deal to acquire almost all of Merck KGaA’s US CDMO network will significantly boost its US footprint and capabilities in key areas.
Clinical
Clinical Trials Arena
The WHO has approved the addition of the ChAdOx1 and mRNA-1469 to the Ebola vaccine trial. The post WHO adds two more Ebola vaccines to clinical trial appeared first on Clinical Trials Arena.
Regulatory P Pharmaceutical Executive
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
Industry
Clinical Trials Arena
The October 2026 issue in BMJ Medicine followed up on women who had been pregnant between 2000 and 2022 to determine long-term health outcomes. The post Pregnancy complication indicator for risk of disease appeared first on Clinical Trials Arena.
Industry
MedTech Dive
Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019.
Research B BioPharm International
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
Industry P Pharmaceutical Commerce
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Industry B BioTechniques
Protein design is a hot topic, and despite June’s heatwave, the first London Protein Design Day was full. Full of speakers and poster presenters who sparked scientific discussions with a remarkably engaged audience. Held on June 23, 2026, at Imperial College London (Imperial; UK)…
Industry
STAT Biotech
Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…
Industry P Pharmaceutical Executive
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
Industry
MedTech Dive
The company is rebranding the unit as Olyrian Diagnostics and plans to set it up as a standalone business by mid-2028.
Regulatory B BioPharm International
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio T…
Regulatory B BioPharm International
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Regulatory
PharmaVoice
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.